Image 2_COVID-19 mitigates the response to TKIs in patients with CML via the inhibition of T-cell immunity.pdf

Image 2_COVID-19 mitigates the response to TKIs in patients with CML via the inhibition of T-cell immunity.pdf

Introduction<p>Chronic myeloid leukemia (CML) is a severe hematological malignancy characterized by BCR-ABL fusion gene. The advent of tyrosine kinase inhibitors (TKIs) targeting BCR-ABL has improved the landscape of CML treatment dramatically. The occurrence of coronavirus disease 2019 (COVID...

وصف كامل

محفوظ في:
التفاصيل البيبلوغرافية
المؤلف الرئيسي: Na He (295300) (author)
مؤلفون آخرون: Guosheng Li (1419298) (author), Jinting Liu (398001) (author), Wancheng Liu (7213538) (author), Ruifeng Tian (5987279) (author), Daoxin Ma (212170) (author)
منشور في: 2024
الموضوعات:
Genetic Immunology
Chronic myeloid leukemia
COVID-19
BCR-ABL P210
T cell immunity
TKIs
الوسوم: إضافة وسم
لا توجد وسوم, كن أول من يضع وسما على هذه التسجيلة!

مواد مشابهة

مواد مشابهة